RadianceTx Beta Ophthalmic System Unlocks the Clinical Potential of Glaucoma Surgical Interventions
TUCSON, Ariz. & LONDON–(BUSINESS WIRE)–July 31, 2018–
RadianceTx™, a leader in ophthalmic therapeutic innovation, today announced a $1 million first tranche closing of a targeted $7 million round of financing. The investment will be used to fund development of the Company’s Beta Ophthalmic System for delivery of beta irradiation therapy to improve glaucoma surgery outcomes. Validated in three clinical studies conducted by preeminent ophthalmic research teams, beta therapy has been shown to improve glaucoma surgery outcomes. A recent study reported odds ratios that beta irradiation therapy patients were five and a half times more likely to experience lower intraocular pressure at the end of one year than patients treated with the current standard of care.
Glaucoma is the leading cause of irreversible blindness. The most successful way to prevent vision loss from glaucoma is to lower intraocular pressure with drainage surgery; this surgery shunts fluid out of the eye through a channel created during a trabeculectomy procedure or by a flow-controlled drainage device placed during Minimally Invasive Glaucoma Surgery (MIGS). Despite compelling therapeutic advantages over nonsurgical treatments, drainage surgery and devices are clinically limited by postoperative scarring. RadianceTx’s Beta Ophthalmic System is designed to apply beta therapy to the surgical site to down-regulate fibroblasts that cause scar tissue, keeping the channel open and maintaining reduced intraocular pressure.
Sir Peng Khaw, Consultant Ophthalmic Surgeon and Professor of Glaucoma Studies and Wound Healing, and member of the Board of Directors at RadianceTx said: “For glaucoma surgery to be maximally successful, anti-scarring therapies must be effective, consistent in dosage as well as fast and very easy to administer. In combination with new glaucoma drainage devices, RadianceTx Beta Ophthalmic System could revolutionize the treatment of glaucoma.”
A device solution, RadianceTx Beta Ophthalmic System is designed to topically apply beta therapy to trabeculectomy or MIGS drainage device implantation sites. Currently, scarring prevention involves the complex and time-consuming intra-operative application of antimetabolites (chemotherapy drugs) yet still results in a failure rate approaching 50 percent at three years. Ian Murdoch and colleagues have carried out three randomized controlled trials involving 728 patients which have demonstrated beta therapy’s clinical effectiveness in drainage surgery. The new RadianceTx Beta Ophthalmic System is designed to optimize surgical workflow efficiency by requiring only 25 seconds for beta therapy application, minimizing stray dosing to non-target tissues, and eliminating medical staff exposure to hazardous chemotherapy drugs.
“I am pleased to announce this initial funding for RadianceTx, which allows us to begin commercial development,” said Harry George, President and Chief Financial Officer of RadianceTx. “The RadianceTx team possesses a track record of achieving regulatory market clearances for other medical and ophthalmic devices and is poised to advance the standard of care for glaucoma surgery with the RadianceTx Beta Ophthalmic System.”
The glaucoma device market is growing rapidly. In the United States alone there were 70,000 trabeculectomies in 2017. In the UK, trabeculectomies peaked at greater than 20,000. The Minimally Invasive Glaucoma Surgery (MIGS) device market is expected to grow at a compound annual growth rate of nearly 44 percent to $1.36 billion by 2022.
RadianceTx is a trademark of Radiance Therapeutics, Inc., a Delaware corporation. Radiance Therapeutics, Inc., a leader in ophthalmic therapeutic innovation, is commercializing a clinically demonstrated novel anti-metabolite therapy for glaucoma drainage surgery. For more information, visit: www.radiancetherapeutics.com.
Caution: Investigational Device.